{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:50:59Z","timestamp":1792421459151,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00946","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:57:41Z","timestamp":1591145861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":133,"title":["The Changing Landscape of Autoimmune Hemolytic Anemia"],"prefix":"10.3389","volume":"11","author":[{"given":"Wilma","family":"Barcellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1699-0463.1997.tb00581.x","article-title":"Chronic cold agglutinin disease of the idiopathic type is a premalignant or low-grade malignant lymphoproliferative disease","volume":"105","author":"Berentsen","year":"1997","journal-title":"APMIS"},{"key":"B3","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1002\/ajh.25020","article-title":"Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia","volume":"93","author":"Fattizzo","year":"2018","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects","volume":"9","author":"Fattizzo","year":"2020","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"5","author":"J\u00e4ger","year":"2019","journal-title":"Blood Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/JBM.S190327","article-title":"Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives","volume":"10","author":"Barcellini","year":"2019","journal-title":"J Blood Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E149","DOI":"10.1002\/ajh.24047","article-title":"Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias","volume":"90","author":"Fattizzo","year":"2015","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00277-018-3553-9","article-title":"Prognosis of autoimmune hemolytic anemia in critically ill patients","volume":"98","author":"Lafarge","year":"2019","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e24313","DOI":"10.1371\/journal.pone.0024313","article-title":"Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia","volume":"6","author":"Maura","year":"2011","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ajh.23342","article-title":"B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia","volume":"88","author":"Maura","year":"2013","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease","volume":"183","author":"Malecka","year":"2018","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET Registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5152\/TurkPediatriArs.2016.3928","article-title":"The plethora, clinical manifestations and treatment options of autoimmunity in patients with primary immunodeficiency","volume":"51","author":"Bari\u015f","year":"2016","journal-title":"Turk Pediatri Ars"},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/bmj.280.6216.760","article-title":"Human leucocyte antigens A, B, C, and DRW in idiopathic warm autoimmune haemolytic anaemia","volume":"280","author":"Abdel-Khalik","year":"1980","journal-title":"Br Med J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1046\/j.1537-2995.1996.36111297091742.x","article-title":"Reduced frequency of HLA-DQ6 in individuals with a positive direct antiglobulin test","volume":"36","author":"Wang-Rodriguez","year":"1996","journal-title":"Transfusion"},{"key":"B23","volume-title":"Immune Hemolytic Anemias","author":"Petz","year":"2004"},{"key":"B24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.seminhematol.2015.05.001","article-title":"Immune hemolysis: diagnosis and treatment recommendations","volume":"52","author":"Barcellini","year":"2015","journal-title":"Semin Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"635670","DOI":"10.1155\/2015\/635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia","volume":"2015","author":"Barcellini","year":"2015","journal-title":"Dis Markers"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1537-2995.2009.02533.x","article-title":"A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies","volume":"50","author":"Bartolm\u00e4s","year":"2010","journal-title":"Transfusion"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","author":"Fattizzo","year":"2020","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132490","article-title":"Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): results from the Phase 3 Cardinal Study","volume":"134","author":"R\u00f6th","year":"2019","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17474086.2017.1339597","article-title":"The relationship between idiopathic cytopenias\/dysplasias of uncertain significance(ICUS\/IDUS) and autoimmunity","volume":"10","author":"Barcellini","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/ajh.24618","article-title":"Clinical evolution of autoimmune cytopenias to idiopathic cytopenias\/dysplasias of uncertain significance (ICUS\/IDUS) and bone marrow failure syndromes","volume":"92","author":"Barcellini","year":"2017","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/leu.2017.181","article-title":"CHIP, ICUS, CCUS and other four-letter words","volume":"31","author":"Bejar","year":"2017","journal-title":"Leukemia"},{"key":"B35","first-page":"459","article-title":"Bone marrow mitogen-stimulated direct antiglobulin test in a case of erythroblastic synartesis","volume":"56","author":"Zaninoni","year":"2010","journal-title":"Clin Lab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1537-2995.2012.03942.x","article-title":"Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products","volume":"53","author":"Skeate","year":"2013","journal-title":"Transfusion"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2018.02.005","article-title":"Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Espa\u00f1ol De Trasplante de Medula Osea en Ni\u00f1os (GETMON) and the Grupo Espa\u00f1ol de Trasplante Hematopoyetico (GETH)","author":"Gonz\u00e1lez-Vicent","year":"2018","journal-title":"Transfus Med Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","article-title":"Risk Factors, Treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"24","author":"Kruizinga","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1759-7714.13405","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/hon.2338","article-title":"Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report","volume":"35","author":"Tardy","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:57:44Z","timestamp":1591145864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2020.00946"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00946","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"946"}}